Objective: The aim of this study was to describe recent medication patterns and changes in medication patterns and glycemic control in adolescents and young adults with incident type 2 diabetes (T2D).
| INTRODUCTION
There has been an increase in prevalence of individuals diagnosed with type 2 diabetes before 20 years of age ("youth-onset" diabetes). 1 While many therapies have been tested for safety and efficacy in patients with type 2 diabetes mellitus older than 18 years of age, there are limited data for those with youth-onset diabetes. 2 insulin approximately 2 years after diagnosis. 5 Greater than 50% of the participants were not adequately controlled (A1C ≥ 8%, 64 mmol/ mol), including >50% of those taking insulin-containing therapies alone or in combination with other therapies. With an increasing number of diabetes therapies currently approved for use in adults, the goal of the current study was to expand on the earlier SEARCH work to examine more contemporary treatment patterns and glycemic control over a longer duration of follow-up for adolescents and young adults and an ongoing cohort study, which was developed by recruiting incident cases who had a baseline visit and their first cohort study followup visit after at least 5 years since their initial diagnosis. The overall SEARCH study design has been previously described in detail. 6 Prior SEARCH studies have demonstrated that the physician diagnosis of type 1 and type 2 diabetes agrees well with etiologic assessments and that the participants are reasonably representative of the general US population with the onset of type 1 and type 2 diabetes in childhood or adolescence.
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The current report describes a cross-sectional analysis of adoles- 
| Diabetes treatment regimens

| Statistical analysis
Descriptive summaries were presented with continuous variables Between group and within group comparisons were performed using χ 2 or Fisher's exact test (categorical data) or 1-way ANOVA (continuous data) with a type 1 error rate of 0.05. Statistical analyses were conducted using SAS (version 9.4; SAS Institute, Cary, North Carolina).
| RESULTS
The cross-sectional analysis included 646 adolescents and young adults with incident type 2 diabetes (age at diagnosis 
| Longitudinal analysis of diabetes medication use and glycemic control
The longitudinal analysis included a total of 322 adolescents and young adults with newly diagnosed type 2 diabetes. At the time of the baseline visit, the majority were receiving metformin and/or insulin, with approximately 10% reporting lifestyle only (Table 3) . At the baseline visit, those reporting the use of metformin monotherapy had a significantly lower unadjusted A1C (6.4% AE 1.4%) compared to those on insulin monotherapy (8.4% AE 2.2%, P < .001), insulin plus an ODM (7.7% AE 2.2%, P < .001), or other ODM (7.3% AE 2.1%, P < .05), and comparable unadjusted A1C levels to those with no use of diabetes medications (6.6% AE 2.4%) ( Table 3) .
At follow-up, a larger proportion of participants had changed medication category than remained on their baseline therapy (P < .001) ( were not using a diabetes medication at follow-up with an A1C < 6.5% (47.5 mmol/mol), including 18% of participants receiving metformin only and approximately 7% in the insulin (AEODM) groups.
| DISCUSSION
The current cross-sectional analysis confirms earlier SEARCH findings that the majority of youths with type 2 diabetes are largely being treated with metformin and/or insulin, which are the only 2 diabetes medications approved for use in children. 5 There was little to no use of which a large proportion of youths with type 2 diabetes being treated with metformin monotherapy did not achieve glycemic goal, a direct comparison between the results of these 2 studies is difficult, given the differences in eligibility criteria, study design, and oversight. 4 Even so, our study results provide further evidence that a large proportion of children and adolescents with youth-onset diabetes are not being treated to goal, which is of significant concern given the increased risk of vascular complications.
The failure of to achieve A1C goal may be multifactorial in nature, with some factors difficult to identify and not all amenable to modification. The current study does not address the question of whether poor glycemic control in adolescents and young adults is attributable to lack of adherence, persistence, or access issues (eg, lack of nutritional counseling). Similarly, we were not able to assess the contribution of lack of treatment intensification by healthcare professionals (sometimes referred to as "clinical inertia"), or other system level barriers. 13 Although the reasons for poor glycemic control were not evaluated in the current study, it should be noted that a majority of participants in the longitudinal cohort study were adults at the time of follow-up, yet there was very limited use of medications approved for adults other than metformin and/or insulin. Given the age of participants at follow-up, one possible explanation could be a lack of tailored clinical programs and policies to support transitioning of care for pediatric patients and loss to the healthcare system. A recent SEARCH study of factors associated with transfer from pediatric to adult care revealed a substantial worsening of glycemic control and loss to follow-up during healthcare transfer. 14 A substantial proportion (15%) of those transitioning from pediatric care reported no medical care after 18 years of age. Insurance status was a major difference between the groups at follow-up with 74% in the no care group being uninsured compared with 15% in the adult care group and only 1.6%
of pediatric participants at baseline being uninsured.
Another important finding of the present study is that the approximately 15% of participants at the time of the follow-up visit were not taking glycemic medications and had an A1C < 6.5% (47.5 mmol/mol).
The percentage of participants not taking any glycemic medications is higher compared with expert consensus that fewer than 10% of youth with type 2 diabetes will attain glycemic goals through lifestyle intervention alone. 2 For participants receiving baseline metformin and/or insulin, approximately 13% in the current study were not taking a diabetes medication at follow-up with an A1C within non-diabetic range (<6.5%, 47.5 mmol/mol). These findings may be explained by an initial need for diabetes therapy to stabilize glycemic levels impacted by increased growth hormones and increased insulin resistance that occur during puberty but that over time, lifestyle alone may be sufficient to reduce glycemic levels within normal range in a subset of patients. 
15-17
in diabetes medication regimens and glycemic control for adolescents and young adults with type 2 diabetes, SEARCH baseline and follow-up visits
